Nabriva Therapeutics plc

Nabriva Therapeutics plc is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. The momentum for this stock is not very good. Nabriva Therapeutics plc is not a good value stock. Nabriva Therapeutics plc is not a good growth stock. Nabriva Therapeutics plc is not very popular among insiders. Nabriva Therapeutics plc is a mediocre stock to choose.

Nabriva Therapeutics Plc is a clinical stage biopharmaceutical company, which engages in the researc...

News

StockNews.com Begins Coverage on Nabriva Therapeutics (NASDAQ:NBRV)

Ticker Report StockNews.com started coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV Free Report) in a report issued on Thursday morning. The firm issued a hold rating on the biotechnology companys stock. Nabriva Therapeutics Price Performance Shares of NBRV opened at $1.62 on Thursday. The ...\n more…

Nabriva Therapeutics (NASDAQ:NBRV) Coverage Initiated at StockNews.com

Zolmax Research analysts at StockNews.com initiated coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV Get Free Report) in a research report issued to clients and investors on Thursday. The firm set a hold rating on the biotechnology companys stock. Nabriva Therapeutics Price Performance Shares of ...\n more…

Nabriva Therapeutics (NASDAQ:NBRV) Coverage Initiated at StockNews.com

Ticker Report Stock analysts at StockNews.com began coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV Get Free Report) in a research note issued on Wednesday. The firm set a hold rating on the biotechnology companys stock. Nabriva Therapeutics Price Performance NBRV opened at $1...\n more…

Nabriva Therapeutics (NASDAQ:NBRV) Now Covered by Analysts at StockNews.com

Zolmax StockNews.com began coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV Free Report) in a research note issued to investors on Wednesday. The firm issued a hold rating on the biotechnology companys stock. Nabriva Therapeutics Price Performance NASDAQ NBRV opened at $1.52 on Wednesday. The ...\n more…

Nabriva Therapeutics plc (NASDAQ:NBRV) Short Interest Up 27.4% in June

Zolmax Nabriva Therapeutics plc (NASDAQ:NBRV Free Report) was the recipient of a significant increase in short interest in the month of June. As of June 15th, there was short interest totalling 35,300 shares, an increase of 27.4% from the May 31st total of 27,700 shares. Approximately 1.2% of the companys ...\n more…

Nabriva Therapeutics (NASDAQ:NBRV) Coverage Initiated at StockNews.com

Ticker Report Research analysts at StockNews.com assumed coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV Free Report) in a research report issued to clients and investors on Tuesday. The brokerage set a hold rating on the biotechnology companys stock. Nabriva Therapeutics ...\n more…